Finally, IGF2BP3 played a role in stabilizing MYC by recognizing N6-methyladenosine (m6A) modifications.<h4>Conclusion</h4>The LL22NC03-IGF2BP3-MYC regulatory axis is critically involved in the progression of HCC, suggesting its potential as a novel therapeutic target for this malignancy. This evidence concerns the gene MYC and hepatocellular carcinoma.